Colorectal neoplasia-associated DNA marker

"Colorectal neoplasia-associated DNA marker detection" does **not** refer to a single molecular target such as a receptor, enzyme, or protein. Instead, it describes a **diagnostic approach** that detects multiple genetic and epigenetic alterations associated with colorectal cancer and advanced adenomas in stool samples. This method is exemplified by the multitarget stool DNA (mt-sDNA) test—commercially known as Cologuard—which screens for several specific biomarkers shed from neoplastic cells into the colon lumen and excreted in feces[1][8]. The most commonly detected markers include methylation changes in genes like BMP3 and NDRG4, point mutations in oncogenes such as KRAS (and sometimes BRAF or PIK3CA), and the presence of occult blood[2][8]. These tests are used for noninvasive screening of average-risk adults for colorectal cancer but are not considered therapeutic targets themselves; rather, they represent a panel of diagnostic biomarkers. Therefore, this entry is not appropriate as a canonical drug target. Key points supporting "is_incorrect": - The term refers to an assay/panel rather than an individual molecular entity. - It is not itself a therapeutic target but rather describes what is being detected by screening tools. - No drugs interact directly with these "markers"; instead they serve as indicators for disease presence[1][6][8]. If you need structured information on one of the specific genes or proteins included within these panels—such as "KRAS," "BMP3," or "NDRG4"—please specify which one.

Other names

Multitarget stool DNA markermt-sDNA markersDNA-FIT biomarkerCologuard markers